Biohaven (BHVN) vs Mesoblast (MESO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Biohaven (BHVN) has outperformed Mesoblast (MESO) over the past year, losing 22.2% versus a loss of 30.4%. Biohaven is the larger company by market cap ($1.80 billion vs $1.79 billion), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BHVN | MESO |
|---|---|---|
| Share price | $11.93 | $13.75 |
| Market cap | $1.80B | $1.79B |
| 1-day change | +0.42% | -1.36% |
| YTD return | +5.67% | -23.78% |
| 1-year return | -22.23% | -30.38% |
| 5-year return | — | +21.04% |
| Forward P/E | — | 30.22 |
| EPS (TTM) | $-4.56 | $-0.44 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $17.20M |
| Revenue growth (YoY) | — | +191.39% |
| Net income (latest FY) | $-738.82M | $-102.14M |
| Gross margin | — | 70.17% |
| Net margin | — | -593.92% |
| 52-week high | $18.57 | $21.50 |
| 52-week low | $7.48 | $13.05 |
| Distance from 52-week high | -35.74% | -36.05% |
| Analyst consensus | buy | buy |
| Avg. price target upside | +78.29% | +169.09% |
| Average volume | 2.62M | 232.53K |
| Shares outstanding | 151.04M | 129.85M |
| Employees | 274 | 108 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Biohaven
BHVN stock →Biohaven Ltd., a biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for immunology, neuroscience, and oncology therapeutic areas worldwide. It develops BHV-1300, which is in Phase 2 clinical trial to treat Graves' disease and rheumatoid arthritis; BHV-1400 that is in Phase 2 clinical trial for treating IgA nephropathy; BHV-1600, which is in Phase 1 clinical trial for the treatment of peripartum cardiomyopathy; BHV-8000 that is in Phase 3 clinical trial for treating Parkinson's disease; Opakalim, which is in Phase 3 clinical trial for the treatment of focal epilepsy; BHV-2100 that is in Phase 2 clinical trial for the treatment of pain disorders; and BHV-2000, which is in Phase 2 clinical trial for treating obesity.
Health Care · Biotechnology: Pharmaceutical Preparations · 274 employees
About Mesoblast
MESO stock →Mesoblast Limited, together with its subsidiaries, engages in the development of regenerative medicine products in Australia. The company's proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 108 employees
BHVN vs MESO FAQ
Which is bigger, Biohaven or Mesoblast?
Biohaven (BHVN) is larger, with a market capitalization of $1.80B compared with $1.79B for Mesoblast (MESO).
Which stock has performed better over the past year, BHVN or MESO?
BHVN returned -22.23% over the past 12 months, compared with -30.38% for MESO (price return, excluding dividends). Past performance does not predict future results.
Are Biohaven and Mesoblast in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Pharmaceutical Preparations for Biohaven and Biotechnology: Biological Products (No Diagnostic Substances) for Mesoblast.